A Study of PER-001 in Participants With Open-Angle Glaucoma

Status Recruiting

Clinical Trial Summary

This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.

Clinical Trial Description

This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, SAD study to investigate the ocular and systemic safety and tolerability of two dose levels of PER-001, in participants with advanced OAG. Phase 1 will enroll up to approximately 12 participants. Phase 2a is a randomized, single-masked (participant) study to further investigate the ocular and systemic safety and tolerability of the two dose levels of PER-001 Intravitreal Implants in participants with progressing glaucoma. Participants who meet entry criteria will be randomized to receive either dose of PER-001 or sham control. In Phase 2a, a total of approximately 24 participants (12 in each Cohort, will be randomized). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05822245
Study type	Interventional
Source	Perfuse Therapeutics, Inc.
Contact	Andrew Melie
Phone	415-294-8750
Email	info@perfusetherapeutics.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	May 25, 2023
Completion date	January 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01157364` - Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension	Phase 1/Phase 2
Completed	`NCT02558374` - Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT01444040` - Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost	Phase 4
Completed	`NCT01444105` - Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty	N/A
Completed	`NCT01426867` - A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%	Phase 2
Completed	`NCT01456390` - Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents	N/A
Completed	`NCT01415401` - Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada	Phase 4
Completed	`NCT01443988` - Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost	Phase 4
Completed	`NCT01340014` - Patient Preference Comparison of AZARGA Versus COSOPT	Phase 4
Completed	`NCT01487655` - Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Glaucoma Patients	N/A
Completed	`NCT01455467` - Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery	N/A
Completed	`NCT00759239` - Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension	Phase 4
Completed	`NCT00397241` - 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations	Phase 4
Completed	`NCT00918346` - Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation	Phase 3
Completed	`NCT00273481` - Cosopt Versus Xalacom	Phase 4
Completed	`NCT00716742` - Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)	N/A
Completed	`NCT02558400` - Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension	Phase 3
Withdrawn	`NCT03648229` - African Glaucoma Laser Trial	Phase 4
Completed	`NCT01978600` - Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension	Phase 4
Completed	`NCT01699464` - A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months	Phase 2